Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Welch Cancer Center
mi
from
Sheridan, WY
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Allan Blair Cancer Centre
mi
from
Regina,
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Allan Blair Cancer Centre
mi
from
Regina,
Click here to add this to my saved trials
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
Status: Enrolling
Updated:  10/7/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
Status: Enrolling
Updated: 10/7/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
San Francisco, CA
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Washington,
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Chicago, IL
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Kansas City, MO
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
New York, NY
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Cleveland, OH
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Portland, OR
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Nashville, TN
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Houston, TX
Panitumumab Pediatric Study
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Status: Enrolling
Updated:  10/7/2015
Fremont Area Medical Center
mi
from
Fremont, NE
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Status: Enrolling
Updated: 10/7/2015
Fremont Area Medical Center
mi
from
Fremont, NE
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Clinica Viedma
mi
from
Viedma,
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Clinica Viedma
mi
from
Viedma,
Click here to add this to my saved trials
Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue
Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue
Status: Enrolling
Updated:  10/7/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue
Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue
Status: Enrolling
Updated: 10/7/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Swedish-American Regional Cancer Center
mi
from
Rockford, IL
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Swedish-American Regional Cancer Center
mi
from
Rockford, IL
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Click here to add this to my saved trials
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated:  10/7/2015
Dickinson County Healthcare System
mi
from
Iron Mountain, MI
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
Status: Enrolling
Updated: 10/7/2015
Dickinson County Healthcare System
mi
from
Iron Mountain, MI
Click here to add this to my saved trials